Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Infectious Agents in Multiple Sclerosis: Viral Triggers, Antibody-Mediated Autoimmunity, and Parasitic Immunomodulation.

Biomolecules·2026
Same author

Pde4 mediates MHCII expression in oligodendroglia.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Microglia promote vascular remodeling in a mouse model of chronic stress.

Brain, behavior, and immunity·2026
Same author

Editorial: Novel CNS targeting molecules, methods, and therapeutics in multiple sclerosis.

Frontiers in immunology·2025
Same author

Targeting autophagy and plasminogen activator inhibitor-1 increases survival and remodels the tumor microenvironment in glioblastoma.

Journal of experimental & clinical cancer research : CR·2025
Same author

Oligodendroglia Are Primed for Antigen Presentation in Response to Chronic Stress-Induced Microglial-Derived Inflammation.

Glia·2024

Related Experiment Video

Updated: Dec 1, 2025

Characterization and Isolation of Mouse Primary Microglia by Density Gradient Centrifugation
10:21

Characterization and Isolation of Mouse Primary Microglia by Density Gradient Centrifugation

Published on: February 16, 2018

19.9K

Guanabenz modulates microglia and macrophages during demyelination.

Kaitlyn Koenig Thompson1, Stella E Tsirka2

  • 1Department of Pharmacological Sciences, Stony Brook University, Stony Brook, NY, 11794-8651, USA.

Scientific Reports
|November 10, 2020
PubMed
Summary

Guanabenz, an antihypertensive drug, shows promise in treating multiple sclerosis (MS) by reducing harmful immune cell activity in the brain. This may offer a safer therapeutic option for managing MS inflammation.

More Related Videos

Rapid and Refined CD11b Magnetic Isolation of Primary Microglia with Enhanced Purity and Versatility
07:54

Rapid and Refined CD11b Magnetic Isolation of Primary Microglia with Enhanced Purity and Versatility

Published on: April 13, 2017

10.2K
Assessing Microglial Phagocytosis of Myelin Debris in vitro Under Repeated Magnetic Stimulation
08:34

Assessing Microglial Phagocytosis of Myelin Debris in vitro Under Repeated Magnetic Stimulation

Published on: June 17, 2025

731

Related Experiment Videos

Last Updated: Dec 1, 2025

Characterization and Isolation of Mouse Primary Microglia by Density Gradient Centrifugation
10:21

Characterization and Isolation of Mouse Primary Microglia by Density Gradient Centrifugation

Published on: February 16, 2018

19.9K
Rapid and Refined CD11b Magnetic Isolation of Primary Microglia with Enhanced Purity and Versatility
07:54

Rapid and Refined CD11b Magnetic Isolation of Primary Microglia with Enhanced Purity and Versatility

Published on: April 13, 2017

10.2K
Assessing Microglial Phagocytosis of Myelin Debris in vitro Under Repeated Magnetic Stimulation
08:34

Assessing Microglial Phagocytosis of Myelin Debris in vitro Under Repeated Magnetic Stimulation

Published on: June 17, 2025

731

Area of Science:

  • Neuroimmunology
  • Pharmacology

Background:

  • Multiple sclerosis (MS) is an autoimmune disease causing central nervous system damage.
  • Current MS therapies have suboptimal efficacy and adverse effects.
  • Guanabenz, an antihypertensive drug, may have neuroprotective and immunomodulatory properties.

Purpose of the Study:

  • To investigate the immunomodulatory effects of guanabenz on microglia and macrophages in the context of multiple sclerosis.
  • To evaluate guanabenz's therapeutic potential in preclinical models of MS.

Main Methods:

  • Utilized the experimental autoimmune encephalomyelitis (EAE) mouse model to assess guanabenz's impact on immune cell infiltration and inflammation.
  • Employed the cuprizone model to evaluate guanabenz's effects on demyelination and remyelination independent of adaptive immunity.
  • Analyzed microglial and macrophage activation and oligodendrocyte survival.

Main Results:

  • Guanabenz administration in the EAE model significantly reduced pro-inflammatory microglia and macrophages, indicating immunomodulation.
  • In the cuprizone model, guanabenz did not improve remyelination or oligodendrocyte numbers, with less dramatic effects on microglial activation.
  • These findings suggest guanabenz's therapeutic benefits in MS are primarily linked to its anti-inflammatory actions.

Conclusions:

  • Guanabenz demonstrates significant immunomodulatory effects, reducing detrimental immune responses in the central nervous system.
  • The drug shows potential as a therapeutic agent for multiple sclerosis by targeting inflammation with a favorable safety profile.
  • Further research into guanabenz could lead to novel, safer treatments for MS patients.